ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03060629
Recruitment Status : Recruiting
First Posted : February 23, 2017
Last Update Posted : March 29, 2018
Sponsor:
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 2, 2020
  Estimated Study Completion Date : February 1, 2022